Chemomab Therapeutics (CMMB) Competitors $1.36 +0.02 (+1.11%) As of 12:10 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CMMB vs. SAVA, MNOV, STRO, GNTA, TELO, VTVT, ANL, JSPR, MIST, and CRBUShould you be buying Chemomab Therapeutics stock or one of its competitors? The main competitors of Chemomab Therapeutics include Cassava Sciences (SAVA), MediciNova (MNOV), Sutro Biopharma (STRO), Genenta Science (GNTA), Telomir Pharmaceuticals (TELO), vTv Therapeutics (VTVT), Adlai Nortye (ANL), Jasper Therapeutics (JSPR), Milestone Pharmaceuticals (MIST), and Caribou Biosciences (CRBU). These companies are all part of the "pharmaceutical products" industry. Chemomab Therapeutics vs. Cassava Sciences MediciNova Sutro Biopharma Genenta Science Telomir Pharmaceuticals vTv Therapeutics Adlai Nortye Jasper Therapeutics Milestone Pharmaceuticals Caribou Biosciences Chemomab Therapeutics (NASDAQ:CMMB) and Cassava Sciences (NASDAQ:SAVA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, media sentiment, earnings, risk, analyst recommendations, dividends, valuation and community ranking. Does the MarketBeat Community believe in CMMB or SAVA? Cassava Sciences received 79 more outperform votes than Chemomab Therapeutics when rated by MarketBeat users. However, 65.52% of users gave Chemomab Therapeutics an outperform vote while only 64.47% of users gave Cassava Sciences an outperform vote. CompanyUnderperformOutperformChemomab TherapeuticsOutperform Votes1965.52% Underperform Votes1034.48% Cassava SciencesOutperform Votes9864.47% Underperform Votes5435.53% Do analysts recommend CMMB or SAVA? Chemomab Therapeutics presently has a consensus price target of $9.00, indicating a potential upside of 559.34%. Cassava Sciences has a consensus price target of $54.50, indicating a potential upside of 3,360.32%. Given Cassava Sciences' higher probable upside, analysts plainly believe Cassava Sciences is more favorable than Chemomab Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Chemomab Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Cassava Sciences 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Is CMMB or SAVA more profitable? Cassava Sciences' return on equity of -88.05% beat Chemomab Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Chemomab TherapeuticsN/A -101.70% -76.18% Cassava Sciences N/A -88.05%-64.98% Do institutionals and insiders believe in CMMB or SAVA? 46.0% of Chemomab Therapeutics shares are held by institutional investors. Comparatively, 38.0% of Cassava Sciences shares are held by institutional investors. 11.9% of Chemomab Therapeutics shares are held by insiders. Comparatively, 9.0% of Cassava Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media favor CMMB or SAVA? In the previous week, Chemomab Therapeutics had 3 more articles in the media than Cassava Sciences. MarketBeat recorded 5 mentions for Chemomab Therapeutics and 2 mentions for Cassava Sciences. Chemomab Therapeutics' average media sentiment score of 1.04 beat Cassava Sciences' score of 0.93 indicating that Chemomab Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Chemomab Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cassava Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings and valuation, CMMB or SAVA? Chemomab Therapeutics is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioChemomab TherapeuticsN/AN/A-$24.22M-$0.90-1.52Cassava SciencesN/AN/A-$97.22M-$1.45-1.09 Which has more risk & volatility, CMMB or SAVA? Chemomab Therapeutics has a beta of 0.66, indicating that its stock price is 34% less volatile than the S&P 500. Comparatively, Cassava Sciences has a beta of -1.48, indicating that its stock price is 248% less volatile than the S&P 500. SummaryChemomab Therapeutics beats Cassava Sciences on 10 of the 15 factors compared between the two stocks. Get Chemomab Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CMMB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CMMB vs. The Competition Export to ExcelMetricChemomab TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$19.60M$6.72B$5.49B$7.97BDividend YieldN/A3.05%5.11%4.23%P/E Ratio-1.377.3622.6118.58Price / SalesN/A241.71397.51103.15Price / CashN/A65.8538.1834.62Price / Book0.896.486.704.26Net Income-$24.22M$143.43M$3.22B$248.31M7 Day Performance5.81%1.69%1.26%1.34%1 Month Performance31.25%6.58%3.73%3.92%1 Year Performance88.17%-2.63%15.82%5.33% Chemomab Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CMMBChemomab Therapeutics3.5842 of 5 stars$1.37+1.1%$9.00+559.3%+92.9%$19.60MN/A-1.3720Upcoming EarningsShort Interest ↓News CoveragePositive NewsSAVACassava Sciences3.6331 of 5 stars$1.59+1.3%$54.50+3,327.7%-93.0%$76.81MN/A-1.1530News CoverageMNOVMediciNova1.889 of 5 stars$1.560.0%$9.00+477.0%+17.8%$76.51M$1M-6.7810Upcoming EarningsShort Interest ↓News CoverageGap DownSTROSutro Biopharma4.3812 of 5 stars$0.90-0.6%$6.63+638.7%-69.1%$75.66M$62.04M-0.56240Analyst ForecastNews CoverageGap DownGNTAGenenta Science2.2568 of 5 stars$4.08+1.0%$25.00+512.7%+26.3%$74.62MN/A0.007Short Interest ↑News CoverageTELOTelomir Pharmaceuticals2.5117 of 5 stars$2.49-2.4%$15.00+502.4%-61.5%$74.11MN/A-4.291News CoveragePositive NewsVTVTvTv Therapeutics1.7873 of 5 stars$23.17+4.2%$35.50+53.2%-28.5%$73.91M$1.02M-5.119Upcoming EarningsShort Interest ↑News CoverageGap DownANLAdlai Nortye2.6172 of 5 stars$2.00+0.3%$9.00+350.0%-86.7%$73.80M$5M0.00127Short Interest ↓News CoveragePositive NewsHigh Trading VolumeJSPRJasper Therapeutics2.297 of 5 stars$4.80+1.5%$62.50+1,202.1%-77.0%$72.11MN/A-1.0120News CoveragePositive NewsMISTMilestone Pharmaceuticals1.8843 of 5 stars$1.35+5.5%$17.00+1,159.3%-20.0%$72.03M$1M-1.6730News CoveragePositive NewsHigh Trading VolumeCRBUCaribou Biosciences2.461 of 5 stars$0.77-0.3%$9.33+1,109.5%-76.6%$71.77M$9.99M-0.47100Upcoming EarningsAnalyst ForecastAnalyst RevisionHigh Trading Volume Related Companies and Tools Related Companies SAVA Competitors MNOV Competitors STRO Competitors GNTA Competitors TELO Competitors VTVT Competitors ANL Competitors JSPR Competitors MIST Competitors CRBU Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CMMB) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chemomab Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Chemomab Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CMMB Stock Free CMMB Stock Alerts